


PEMRYDI RTU[™] is a prescription medicine used to treat a kind of lung cancer called non-squamous non–small cell lung cancer (NSCLC) and a kind of cancer called malignant pleural mesothelioma, which affects the lining of the lungs and chest wall.

For more information on uses of PEMRYDI RTU[™], please see **Important Safety Information** on pages 6-7.



IMPORTANT SAFETY INFORMATION

PEMRYDI RTU[™] is not for use for the treatment of people with squamous cell non-small cell lung cancer.

PEMRYDI RTU[™] has not been shown to be safe and effective in children.


Do not take PEMRYDI RTU[™] if you have had a severe allergic reaction to any medicine that contains pemetrexed.

Please see Important Safety Information on pages 6-7 and accompanying Prescribing Information in the pocket.



What is PEMRYDI RTU[™]?

PEMRYDI RTU[™] is a treatment approved by the Food and Drug Administration for various types of cancer. Your healthcare provider may prescribe PEMRYDI RTU[™] on its own, or in combination with other medications, to treat:



PEMRYDI RTU[™] is another brand of the drug Alimta[®] (pemetrexed)

RTU stands for *ready-to-use*, and PEMRYDI RTU[™] is the first and only form of pemetrexed that does not need to be reconstituted, diluted, or refrigerated. This means that administering PEMRYDI RTU[™] requires fewer steps and can save time for your care providers and you.


PEMRYDI RTU[™] was approved by the FDA under the 505(b)(2) new drug approval pathway. The 505(b)(2) pathway was created to simplify and speed up the approval process for new drugs that are evolutions of currently approved drugs, with potential for changes in dosage form, strength, formulation, dosing regimen, or route of administration. As with all FDA-approved medicines, drugs approved under this abbreviated pathway undergo rigorous evaluation, so you can be assured of their efficacy, safety, and quality.

How PEMRYDI RTU[™] works to treat your cancer

PEMRYDI RTU[™] is a chemotherapy, a type of medicine that works by stopping or slowing the growth of cancer cells


The human body is made up of trillions of cells. When cells grow old or become damaged, they die off and are replaced by new cells. The body forms new cells through a process of cell growth and multiplication called *cell division*. Sometimes this process malfunctions—abnormal cells don't die and instead keep making new abnormal cells. Cancer results when these abnormal cells grow out of control. These cancer cells may spread to other parts of the body.

PEMRYDI RTU[™] works by disrupting the production of folate, a B vitamin that is needed for cell division. By blocking folate, PEMRYDI RTU[™] interferes with the ability of cancer cells to multiply and continue making new cells. Chemotherapies affect both cancer and normal cells, which can lead to side effects. Over time, most normal cells will recover from the effects of chemotherapy, but cancer cells usually do not recover because they are damaged.



Your healthcare provider may prescribe PEMRYDI RTU[™] with other treatments, including other chemotherapies.

PEMRYDI RTU[™] is given to you by intravenous (IV) infusion into your vein



It is very important to take folic acid and vitamin B₁₂ during your treatment with PEMRYDI RTU[™] to lower your risk of harmful side effects. Your doctor will also prescribe a corticosteroid for you to take the day before each treatment with PEMRYDI RTU[™].

IMPORTANT SAFETY INFORMATION

Before taking PEMRYDI RTU[™], tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems.
- have had radiation therapy.
- are pregnant or plan to become pregnant. PEMRYDI RTU[™] can harm your unborn baby.

Please see Important Safety Information on pages 6-7 and accompanying Prescribing Information in the pocket.

WHEN? Once every 21-day cycle ATION? 10-minute infusion

How many cycles you are given will depend on your

type of cancer and how you respond to treatment.



What are the side effects of PEMRYDI RTU[™]?

Side effects can occur during treatment with PEMRYDI RTU[™]. It is important to stay in close communication with your healthcare provider throughout your treatment.

The most common side effects of PEMRYDI RTU[™] when given alone are:



Side effects differ when PEMRYDI RTU[™] is given with certain chemotherapies

- When given with cisplatin, the most common side effects are vomiting, low white blood cell counts (neutropenia), swelling or sores in your mouth or sore throat, low platelet counts (thrombocytopenia), constipation, and low red blood cell counts (anemia)
- When given with pembrolizumab and platinum chemotherapy, the most common side effects are tiredness and weakness, nausea, constipation, diarrhea, loss of appetite, rash, vomiting, cough, shortness of breath. and fever

Before taking PEMRYDI RTU[™], tell your healthcare provider about all of your medical conditions, including if you:

- Have kidney problems
- Have had radiation therapy
- Are pregnant or plan to become pregnant. PEMRYDI RTU[™] can harm your unborn baby

Serious side effects can occur with PEMRYDI RTU[™]. Contact your healthcare provider right away if you experience any of the following:

- Signs of low blood cell counts, such as infection, fever, bleeding, or severe tiredness during your treatment with PEMRYDI RTU[™]
- Signs of kidney problems, such as decrease in amount of urine
- Signs of severe skin reactions, such as blisters, skin sores, skin peeling, or painful sores, or ulcers in your mouth, nose, throat, or genital area
- Signs of lung problems, such as new or worsening symptoms of shortness of breath, cough, or fever
- Signs of radiation recall, such as swelling, blistering, or a rash that looks like a sunburn in an area that was previously treated with radiation

Please see Important Safety Information on pages 6-7 and accompanying Prescribing Information in the pocket.

Resources for support

Learn more about your disease

You may find it useful to know more about your cancer. Below are some websites that could help you understand what to expect after your diagnosis.

American Cancer	Centers for Disease	The ASCO	National Cancer
Society	Control and Prevention	Foundation	Institute
www.cancer.org	www.cdc.gov	www.conquer.org	www.cancer.gov

The Amneal PATHways[®] program is here to make accessing and paying for your medicine as seamless as possible

When you enroll in the program, you will be connected with one of our Patient Access Specialists who will:

- Help you understand your benefits and insurance coverage
- Discuss affordability options you may be eligible for
- Keep you informed about program updates as they occur

The Amneal PATHways[®] Co-pay Assistance Card



Eligible* commercially insured patients may pay as little as \$0 per treatment with an Amneal product.

Questions? Call 1-866-4-AMNEAL (1-866-426-6325) with any questions or concerns

Monday-Friday, 8:00 AM-8:00 PM ET









Scan the QR code to enroll in the Amneal PATHways® program, and see what affordability options you may be eligible for.



Important Safety Information

What is PEMRYDI RTU[™]?

PEMRYDI RTU[™] is a prescription medicine used to treat two kinds of cancer:

- For non-squamous non-small cell lung cancer (NSCLC),
- PEMRYDI RTU[™] is used as the first treatment in combination with:
- Pembrolizumab and platinum chemotherapy when your lung cancer with no abnormal EGFR or ALK gene has spread (advanced NSCLC)
- Cisplatin when your lung cancer has spread (advanced NSCLC)

PEMRYDI RTU[™] is used alone:

- As maintenance treatment after you have received 4 cycles of chemotherapy that contains platinum for first treatment of your advanced NSCLC and your cancer has not progressed
- When your lung cancer has returned or spread after prior chemotherapy
- PEMRYDI RTU[™] is not for use for the treatment of people with squamous cell NSCLC.
- For malignant pleural mesothelioma, which affects the lining of the lungs and chest wall, PEMRYDI RTU™ is used in combination with cisplatin as the first treatment for malignant pleural mesothelioma that cannot be removed by surgery, or you are not able to have surgery.

PEMRYDI RTU[™] has not been shown to be safe and effective in children.

What is the most important information that I should know about PEMRYDI RTU[™]?

- Do not take PEMRYDI RTU[™] if you have had a severe allergic reaction to any medicine that contains pemetrexed.
- PEMRYDI RTU[™] can suppress bone marrow function, which may cause low blood cell counts.
- Tell your healthcare provider if you have liver or kidney problems. Your dose of PEMRYDI RTU[™] may have to be changed, or PEMRYDI RTU[™] may not be right for you.
- It is very important to take folic acid and vitamin B₁, prior to and during your treatment with PEMRYDI RTU[™] to lower your chances of harmful side effects:
- You must take folic acid every day by mouth beginning 7 days before your first dose of PEMRYDI RTU[™]. Keep taking folic acid daily during the time you are being treated with PEMRYDI RTU[™], and continue taking every day for 21 days after your last dose of PEMRYDI RTU™.
- Your healthcare provider will give you vitamin B injections while you are getting treatment with PEMRYDI RTU[™]. You will get your first vitamin B injection one week before your first dose of PEMRYDI RTU[™], and then about every 9 weeks during treatment.
- Your healthcare provider will prescribe a medicine called a corticosteroid, which you must take 2 times a day the day before, the day of, and the day after each treatment with PEMRYDI RTU[™].
- Your healthcare provider will do blood tests to check for side effects during treatment with PEMRYDI RTU[™]. Your healthcare provider may change your dose of PEMRYDI RTU[™], delay treatment, or stop treatment if you have certain side effects.

What should I tell my healthcare provider before receiving PEMRYDI RTU[™]?

If you are pregnant, planning to become pregnant, or nursing, please tell your healthcare team. PEMRYDI RTU[™] may harm your unborn or nursing baby. Your physician may advise you to use effective contraception (birth control) to prevent pregnancy while you are being treated with PEMRYDI RTU[™].

Tell your healthcare provider about all of your medical conditions, including if you have kidney problems, have had radiation therapy, or are pregnant or plan to become pregnant.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider if you have kidney problems and take a medicine that contains ibuprofen. You should avoid taking ibuprofen for 2 days before, the day of, and 2 days after receiving treatment with PEMRYDI RTU[™].

What are the possible side effects of PEMRYDI RTUTM? PEMRYDI RTU[™] can cause serious side effects, including:

- blood tests to check your blood cell counts regularly during your treatment with PEMRYDI RTU[™]. tiredness during your treatment with PEMRYDI RTU[™].
- become worse. Tell your healthcare provider right away if you have a decrease in amount of urine.
- mouth, nose, throat, or genital area.
- Radiation recall. Radiation recall is a skin reaction that can happen in people who have received radiation blistering, or a rash that looks like a sunburn in an area that was previously treated with radiation.

The most common side effects of PEMRYDI RTU[™] when given alone are tiredness, nausea, and loss of appetite. The most common side effects of PEMRYDI RTU[™] when given with cisplatin are vomiting, swelling or sores in your mouth or sore throat, constipation, low white blood cell counts (neutropenia), low platelet counts (thrombocytopenia), and low red blood cell counts (anemia).

The most common side effects of PEMRYDI RTU[™] when given with pembrolizumab and platinum **chemotherapy are** tiredness and weakness, nausea, constipation, diarrhea, loss of appetite, rash, vomiting, cough, shortness of breath, and fever.

PEMRYDI RTU™ may cause fertility problems in males. This may affect your ability to father a child. It is not known if these effects are reversible. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of PEMRYDI RTU[™].

How is PEMRYDI RTU[™] given?

PEMRYDI RTU[™] is given to you by intravenous (IV) infusion into your vein. The infusion is given over 10 minutes. PEMRYDI RTU[™] is usually given once every 21 days (3 weeks).

For more information about all of the side effects of PEMRYDI RTU[™], please see full Prescribing Information in the pocket.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

• Low blood cell counts. Low blood cell counts can be severe, including low white blood cell counts (neutropenia), low platelet counts (thrombocytopenia), and low red blood cell counts (anemia). Your healthcare provider will do

Tell your healthcare provider right away if you have any signs of infection, fever, bleeding, or severe

Kidney problems, including kidney failure. PEMRYDI RTU[™] can cause severe kidney problems that can lead to death. Severe vomiting or diarrhea can lead to loss of fluids (dehydration), which may cause kidney problems to

Severe skin reactions. Severe skin reactions that may lead to death can happen with PEMRYDI RTU[™]. Tell your healthcare provider right away if you develop blisters, skin sores, skin peeling, or painful sores or ulcers in your

• Lung problems (pneumonitis). PEMRYDI RTU[™] can cause serious lung problems that can lead to death. Tell your healthcare provider right away if you get any new or worsening symptoms of shortness of breath, cough, or fever.

treatment in the past and are treated with PEMRYDI RTU[™]. Tell your healthcare provider if you get swelling,








Treat cancer with **PEMRYDI RTU**™

We at Amneal Biosciences are here to support you with every aspect of your treatment journey. Treating cancer is a team effort. Between your healthcare provider, your treatment team, and our trusted patient support services, you can start your PEMRYDI RTU™ treatment knowing there will always be someone there to help.



IMPORTANT SAFETY INFORMATION

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Tell your healthcare provider if you have kidney problems and take a medicine that contains ibuprofen. You should avoid taking ibuprofen for 2 days before, the day of, and 2 days after receiving treatment with PEMRYDI RTU[™].

Please see Important Safety Information on pages 6-7 and accompanying Prescribing Information in the pocket.

amnealbiosciences.com | amneal.com

Pemrydi RTU[™] is a trademark of Amneal Pharmaceuticals LLC. Alimta® is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates. ©2024 Amneal Pharmaceuticals LLC. All rights reserved. PP-PAT-PEM-US-0002 03/24



Biosciences